1. Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl.
Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S19.
2. Cost of managing constipation among terminally ill cancer patients treated with transdermal fentanyl and 12 hour sustained-release morphine in Ontario, Canada.
Author: TN Flynn & JF Guest.
Source: Journal of Medical Economics 1999; 2: 15-32.
3. Cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl in Ontario, Canada.
Presented at the 15th International Conference on Pharmacoepidemiology, Boston, August 1999 and the 1999 Canadian Palliative Care Conference, London, Ontario, October 1999.
4. Economic impact of low dose polyethylene glycol 3350 plus electrolytes (PEG+E) compared to lactulose in the treatment of idiopathic chronic constipation.
Presented at the British Geriatrics Society Autumn 2000 Meeting, London, October 2000 and the 8th United European Gastroenterology Week, Brussels, November 2000.
5. The economic impact of low dose polyethylene glycol 3350 plus electrolytes compared to lactulose in the management of idiopathic constipation in the UK.
Author: AH Christie, P Culbert & JF Guest
Source: PharmacoEconomics 2002; 20(1): 49-60.
6. Pharmacoeconomic impact of low-dose macrogol 3350 plus electrolytes compared with lactulose in the management of chronic idiopathic constipation among ambulant patients in Belgium.
Author: JF Guest & SJ Varney.
Source: Clinical Drug Investigation 2004; 24(12):719-729.
7. Modelling the costs and consequences of treating paediatric faecal impaction in Australia.
Author: JF Guest & JP Clegg.
Source: Current Medical Research and Opinion 2006;22(11):107-119 in press.
8. Health economic impact of macrogol 3350 plus electrolytes (Movicol/ Movicol Paediatric Plain) compared to enemas and suppositories and manual evacuation in treating paediatric faecal impaction in the UK.
Presented at the annual meeting of the Royal College of Paediatrics and Child Health, York, March 2007 and the 40th annual meeting of the European Society for Paediatric gastroenterology, Hepatology and Nutrition, Barcelona, May 2007.
9. Clinical and economic impact of using macrogol 3350 plus electrolytes in an outpatient setting compared to enemas and suppositories and manual evacuation to treat paediatric faecal impaction based on actual clinical practice in England and Wales.
Authors: JF Guest, DCA Candy, JP Clegg, D Edwards, MT Helter, AK Dale, J Fell, M Cosgrove & G Debelle.
Source: Current Medical Research and Opinion 2007; 23(9): 2213-2225.
10. Cost-effectivness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK.
Authors: JF Guest, JP Clegg & MT Helter.
Source: Current Medical Research and Opinion 2008; 24(7): 1841-1852.
11. Cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK.
Authors: RR Taylor & JF Guest.
Source: Alimentary Pharmacology & Therapeutics 2010; 31(2): 302-312.
<<< Go Back